Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus best supportive care versus best supportive care alone in chemorefractory wild-type KRAS metastatic colorectal cancer
2010-022951-49Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Panitumumab + best supportive care with Best supportive care alone (2 arms). Primary endpoint: Overall survival. Started May 2011; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-022951-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022951-49.